[go: up one dir, main page]

HK1062011A1 - Selective androgen receptor modulators and methods of use thereof - Google Patents

Selective androgen receptor modulators and methods of use thereof Download PDF

Info

Publication number
HK1062011A1
HK1062011A1 HK04104977A HK04104977A HK1062011A1 HK 1062011 A1 HK1062011 A1 HK 1062011A1 HK 04104977 A HK04104977 A HK 04104977A HK 04104977 A HK04104977 A HK 04104977A HK 1062011 A1 HK1062011 A1 HK 1062011A1
Authority
HK
Hong Kong
Prior art keywords
androgen receptor
compound
nhcoch
receptor modulator
selective androgen
Prior art date
Application number
HK04104977A
Other languages
English (en)
French (fr)
Chinese (zh)
Other versions
HK1062011B (en
Inventor
James Dalton
Duane D. Miller
Donghua Yin
Yali He
Original Assignee
University Of Tennessee Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Tennessee Research Foundation filed Critical University Of Tennessee Research Foundation
Publication of HK1062011A1 publication Critical patent/HK1062011A1/en
Publication of HK1062011B publication Critical patent/HK1062011B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/18—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides
    • C07C235/24—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/12—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54366—Apparatus specially adapted for solid-phase testing
    • G01N33/54373—Apparatus specially adapted for solid-phase testing involving physiochemical end-point determination, e.g. wave-guides, FETS, gratings
    • G01N33/5438—Electrodes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Reproductive Health (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)

Claims (40)

  1. Selektive Androgenrezeptor-Modulatorverbindung mit androgener und anaboler in vivo-Aktivität eines Nichtsteroid-Liganden für den Androgenrezeptor mit der Formel: wobei
    X O ist,
    Z NO2, CN, COR oder CONHR ist;
    Y I, CF3, Br, Cl oder SnR3 ist;
    R ein Alkylrest oder OH ist; und
    Q Acetamido oder Trifluoracetamido ist.
  2. Selektive Androgenrezeptor-Modulatorverbindung gemäß Anspruch 1, wobei Z NO2 ist.
  3. Selektive Androgenrezeptor-Modulatorverbindung gemäß Anspruch 1, wobei Y CF3 ist.
  4. Selektive Androgenrezeptor-Modulatorverbindung gemäß Anspruch 1, wobei Q NHCOCH3 ist.
  5. Selektive Androgenrezeptor-Modulatorverbindung gemäß Anspruch 1, wobei Z NO2 ist, Y CF3 ist und Q NHCOCH3 ist.
  6. Zusammensetzung, umfassend eine selektive Androgenrezeptor-Modulatorverbindung (SARM) mit androgener und anaboler in vivo-Aktivität eines Nichtsteroid-Liganden für den Androgenrezeptor, wobei die Verbindung durch die Struktur der Formel (I) dargestellt ist: wobei X O ist;
    Z NO2, CN, COR oder CONHR ist;
    Y I, CF3, Br, Cl oder SnR3 ist;
    R ein Alkylrest oder OH ist; und
    Q Acetamido oder Trifluoracetamido ist.
  7. Zusammensetzung gemäß Anspruch 6, wobei Z NO2 ist.
  8. Zusammensetzung gemäß Anspruch 6, wobei Y CF3 ist.
  9. Zusammensetzung gemäß Anspruch 6, wobei Q NHCOCH3 ist.
  10. Zusammensetzung gemäß Anspruch 6, wobei Z NO2 ist, Y CF3 ist und Q NHCOCH3 ist.
  11. Arzneimittel, umfassend:
    eine wirksame Menge einer selektiven Androgenrezeptor-Modulatorverbindung (SARM) mit androgener und anaboler in vivo-Aktivität eines Nichtsteroid-Liganden für den Androgenrezeptor, wobei die Verbindung durch die Struktur der Formel (I) dargestellt ist:
    wobei X O ist;
    Z NO2, CN, COR oder CONHR ist;
    Y I, CF3, Br, Cl oder SnR3 ist;
    R ein Alkylrest oder OH ist;
    Q Acetamido oder Trifluoracetamido ist; und
    einen pharmazeutisch verträglichen Träger, ein pharmazeutisch verträgliches Verdünnungsmittel oder Salz.
  12. Arzneimittel gemäß Anspruch 11, wobei Z NO2 ist.
  13. Arzneimittel gemäß Anspruch 11, wobei Y CF3 ist.
  14. Arzneimittel gemäß Anspruch 11, wobei Q NHCOCH3 ist.
  15. Arzneimittel gemäß Anspruch 11, wobei Z NO2 ist, Y CF3 ist und Q NHCOCH3 ist.
  16. Verfahren zum Binden einer selektiven Androgenrezeptor-Modulatorverbindung an einen Androgenrezeptor, umfassend den Schritt des in vitro-Kontaktierens des Androgenrezeptors mit einer selektiven Androgenrezeptor-Modulatorverbindung (SARM) mit androgener und anaboler in vivo-Aktivität eines Nichtsteroid-Liganden für den Androgenrezeptor, in einer zum Binden der selektiven Androgenrezeptor-Modulatorverbindung an den Androgenrezeptor wirksamen Menge, wobei die Verbindung durch die Struktur der Formel (I) dargestellt ist: wobei X O ist;
    Z NO2, CN, COR oder CONHR ist;
    Y I, CF3, Br, Cl oder SnR3 ist;
    R ein Alkylrest oder OH ist; und
    Q Acetamido oder Trifluoracetamido ist.
  17. Verfahren gemäß Anspruch 16, wobei Z NO2 ist.
  18. Verfahren gemäß Anspruch 16, wobei Y CF3 ist.
  19. Verfahren gemäß Anspruch 16, wobei Q NHCOCH3 ist.
  20. Verfahren gemäß Anspruch 16, wobei Z NO2 ist, Y CF3 ist und Q NHCOCH3 ist.
  21. Verwendung einer selektiven Androgenrezeptor-Modulatorverbindung (SARM) mit androgener und anaboler in vivo-Aktivität eines Nichtsteroid-Liganden für den Androgenrezeptor, in einer zum Unterdrücken der Spermaproduktion wirksamen Menge, wobei die Verbindung durch die Struktur der Formel (I) dargestellt ist: wobei X O ist;
    Z NO2, CN, COR oder CONHR ist;
    Y I, CF3, Br, Cl oder SnR3 ist;
    R ein Alkylrest oder OH ist; und
    Q Acetamido oder Trifluoracetamido ist,
    für die Herstellung eines Medikaments zum Unterdrücken der Spermatogenese in einem Individuum.
  22. Verwendung gemäß Anspruch 21, wobei Z NO2 ist.
  23. Verwendung gemäß Anspruch 21, wobei Y CF3 ist.
  24. Verwendung gemäß Anspruch 21, wobei Q NHCOCH3 ist.
  25. Verwendung gemäß Anspruch 21, wobei Z NO2 ist, Y CF3 ist und Q NHCOCH3 ist.
  26. Verwendung einer selektiven Androgenrezeptor-Modulatorverbindung (SARM) mit androgener und anaboler in vivo-Aktivität eines Nichtsteroid-Liganden für den Androgenrezeptor in einer zum Binden der selektiven Androgenrezeptor-Modulatorverbindung an den Androgenrezeptor und zum Bewirken einer Änderung in einem androgenabhängigen Zustand ausreichenden Menge, wobei die Verbindung durch die Struktur der Formel (I) dargestellt ist: wobei X O ist;
    Z NO2, CN, COR oder CONHR ist;
    Y I, CF3, Br, Cl oder SnR3 ist;
    R ein Alkylrest oder OH ist; und
    Q Acetamido oder Trifluoracetamido ist,
    für die Herstellung eines Medikaments zur Hormontherapie.
  27. Verwendung gemäß Anspruch 26, wobei Z NO2 ist.
  28. Verwendung gemäß Anspruch 26, wobei Y CF3 ist.
  29. Verwendung gemäß Anspruch 26, wobei Q NHCOCH3 ist.
  30. Verwendung gemäß Anspruch 26, wobei Z NO2 ist, Y CF3 ist und Q NHCOCH3 ist.
  31. Verwendung einer selektiven Androgenrezeptor-Modulatorverbindung (SARM) mit androgener und anaboler in vivo-Aktivität eines Nichtsteroid-Liganden für den Androgenrezeptor in einer zum Binden der selektiven Androgenrezeptor-Modulatorverbindung an den Androgenrezeptor und Bewirken einer Änderung in einem androgenabhängigen Zustand ausreichenden Menge, wobei die Verbindung durch die Struktur der Formel (I) dargestellt ist: wobei X O ist;
    Z NO2, CN, COR oder CONHR ist;
    Y I, CF3, Br, Cl oder SnR3 ist;
    R ein Alkylrest oder OH ist; und
    Q Acetamido oder Trifluoracetamido ist,
    für die Herstellung eines Medikaments zur Behandlung eines Individuums mit einem verwandten Hormonzustand.
  32. Verwendung gemäß Anspruch 31, wobei Z NO2 ist.
  33. Verwendung gemäß Anspruch 31, wobei Y CF3 ist.
  34. Verwendung gemäß Anspruch 31, wobei Q NHCOCH3 ist.
  35. Verwendung gemäß Anspruch 31, wobei Z NO2 ist, Y CF3 ist und Q NHCOCH3 ist.
  36. Verwendung einer selektiven Androgenrezeptor-Modulatorverbindung (SARM) mit androgener und anaboler in vivo-Aktivität eines Nichtsteroid-Liganden für den Androgenrezeptor, wobei die Verbindung durch die Struktur der Formel (I) dargestellt ist: wobei X O ist;
    Z NO2, CN, COR oder CONHR ist;
    Y I, CF3, Br, Cl oder SnR3 ist;
    R ein Alkylrest oder OH ist; und
    Q Acetamido oder Trifluoracetamido ist,
    für die Herstellung eines Medikaments zur Behandlung eines Patienten mit Prostatakrebs.
  37. Verwendung gemäß Anspruch 36, wobei Z NO2 ist.
  38. Verwendung gemäß Anspruch 36, wobei Y CF3 ist.
  39. Verwendung gemäß Anspruch 36, wobei Q NHCOCH3 ist.
  40. Verwendung gemäß Anspruch 36, wobei Z NO2 ist, Y CF3 ist und Q NHCOCH3 ist.
HK04104977.5A 2000-08-24 2001-08-23 Selective androgen receptor modulators and methods of use thereof HK1062011B (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US64497000A 2000-08-24 2000-08-24
US09/644,970 2000-08-24
US30008301P 2001-06-25 2001-06-25
US60/300,083 2001-06-25
PCT/US2001/026328 WO2002016310A1 (en) 2000-08-24 2001-08-23 Selective androgen receptor modulators and methods of use thereof

Publications (2)

Publication Number Publication Date
HK1062011A1 true HK1062011A1 (en) 2004-10-15
HK1062011B HK1062011B (en) 2007-05-04

Family

ID=

Also Published As

Publication number Publication date
JP2006306880A (ja) 2006-11-09
CA2420279C (en) 2011-07-19
CN1230418C (zh) 2005-12-07
DK1401801T3 (da) 2007-03-05
WO2002016310A9 (en) 2002-07-18
PT1491524E (pt) 2009-04-16
EP1401801A1 (de) 2004-03-31
HRP20030118A2 (en) 2005-02-28
CY1110459T1 (el) 2015-04-29
EP2284149A1 (de) 2011-02-16
MXPA03001632A (es) 2004-09-10
EP1491524A3 (de) 2005-04-20
CA2420279A1 (en) 2002-02-28
AU2001285230B2 (en) 2007-01-25
AU2001285230C1 (en) 2008-03-13
CY1105956T1 (el) 2011-04-06
US6569896B2 (en) 2003-05-27
EP1491524B1 (de) 2009-02-18
EP1491524A2 (de) 2004-12-29
EA007101B1 (ru) 2006-06-30
PT1401801E (pt) 2007-02-28
US20020099096A1 (en) 2002-07-25
EA200501269A1 (ru) 2006-02-24
JP2004518617A (ja) 2004-06-24
EP1401801A4 (de) 2004-08-18
ES2275717T3 (es) 2007-06-16
WO2002016310A1 (en) 2002-02-28
DE60137728D1 (de) 2009-04-02
ATE423092T1 (de) 2009-03-15
ATE344233T1 (de) 2006-11-15
DK1491524T3 (da) 2009-05-04
AU8523001A (en) 2002-03-04
EP1401801B1 (de) 2006-11-02
ES2321933T3 (es) 2009-06-15
EP1705174A1 (de) 2006-09-27
CN1736371B (zh) 2010-05-12
DE60124322T2 (de) 2007-05-31
DE60124322D1 (de) 2006-12-14
HK1072243A1 (en) 2005-08-19
EA200300283A1 (ru) 2003-08-28
BR0114801A (pt) 2003-10-14
CN1471508A (zh) 2004-01-28
SI1401801T1 (sl) 2007-04-30
KR20030061783A (ko) 2003-07-22
EA014224B1 (ru) 2010-10-29
CN1736371A (zh) 2006-02-22
HRP20030118B1 (en) 2008-06-30
GEP20053586B (en) 2005-07-25

Similar Documents

Publication Publication Date Title
EP1401801B1 (de) Selektive modulatoren des andro genrezeptors und methoden zu deren verwendung
US6492554B2 (en) Selective androgen receptor modulators and methods of use thereof
US6998500B2 (en) Selective androgen receptor modulators and methods of use thereof
EP1558565B1 (de) Halogenierte selektiveandrogenrezeptormodulatoren und verfahren zu deren anwendung
AU2001285230A1 (en) Selective androgen receptor modulators and methods of use thereof
US7741371B2 (en) Selective androgen receptor modulators and methods of use thereof
US20030232792A1 (en) Selective androgen receptor modulators and methods of use thereof
US20030022868A1 (en) Selective androgen receptor modulators and methods of use thereof
US20040260108A1 (en) Metabolites of selective androgen receptor modulators and methods of use thereof
US20020173495A1 (en) Selective androgen receptor modulators and methods of use thereof
US7595402B2 (en) Prodrugs of selective androgen receptor modulators and methods of use thereof
AU2006201538B2 (en) Selective androgen receptor modulators and methods of use thereof
HK1062011B (en) Selective androgen receptor modulators and methods of use thereof
HK1100921A (en) Selective androgen receptor modulators and methods of use thereof
HK1072243B (en) Selective androgen receptor modulators and methods of use thereof
CA2541871A1 (en) Selective androgen receptor modulators and methods of use thereof
HK1097826A (en) Selective androgen receptor modulators and methods of use thereof
HK1080070B (en) Halogenated selective androgen receptor modulators and methods of use thereof
HK1156298A (en) Selective androgen receptor modulators and methods of use thereof

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20120823